Investor Relations

Financial Releases

Date Title and Summary Additional Formats
Toggle Summary Intersect ENT Reports Fourth Quarter and Full Year 2016 Results
Q4 2016 Revenue Increased 29% with Gross Margin of 84% Full Year 2016 Revenue Increased 28% with Gross Margin of 83% MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions,
View HTML
Toggle Summary Intersect ENT to Report Fourth Quarter and Year 2016 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it will release financial results for its fourth quarter and year 2016 on February 28, 2017 .
View HTML
Toggle Summary Intersect ENT to Present at LEERINK Partners Global Healthcare Conference
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq:XENT) a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced that management is scheduled to present an overview of the company's business at the 6 th Annual LEERINK
View HTML
Toggle Summary Intersect ENT Reports Preliminary Q4 and Year 2016 Revenue
Full Year Revenue Grew 28% Year Over Year MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT , Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported preliminary unaudited revenue for the fourth quarter and year
View HTML
Toggle Summary Intersect ENT to Present at the 35th Annual J.P. Morgan Healthcare Conference
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq: XENT ), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced that management is scheduled to present an overview of the company's business, including certain
View HTML
Toggle Summary Intersect ENT to Present at the Piper Jaffray 28th Annual Healthcare Conference
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq:XENT) today announced that management will present an overview of the company's business at the 28 th Annual Piper Jaffray Healthcare Conference in New York . The presentation is scheduled for 4:30pm ET on November 29, 2016 , at the
View HTML
Toggle Summary Intersect ENT to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT) today announced that management will present an overview of the company's business at the 10 th Annual Canaccord Genuity Medical Technology & Diagnostics Forum . The presentation is scheduled for 2:30pm ET on November 17, 2016
View HTML
Toggle Summary Intersect ENT Reports Third Quarter 2016 Results
Revenue Increased 30% Year Over Year; Gross Margin at 85% MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the third quarter ended
View HTML
Toggle Summary Intersect ENT Schedules Third Quarter 2016 Earnings Release and Conference Call for November 2, 2016
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it plans to release third quarter financial results after market close on November 2, 2016 .
View HTML
Toggle Summary Intersect ENT Reports Second Quarter 2016 Results
Revenue Increased 27% Year Over Year; Gross Margin at 84% MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the second quarter ended
View HTML